# Question

In an 82-year-old female with acute kidney injury characterized by a creatinine increase from 1.10 to 1.50 mg/dL within 18 hours post-ICU admission, how should treatment be adjusted considering comorbid congestive heart failure, myocardial infarction, peripheral vascular disease, current use of vasopressors, diuretics, and anticoagulants, and contraindications related to potential fluid overload and electrolyte imbalances, while optimizing renal function and cardiovascular stability?

**Vectors:** `data/real_vectors.jsonl` | topk=5, rerank=False, topn=5

**Vision:** 6 figure(s) sent as `image_url` (pixels). max=6 | VISION_MAX_EDGE=1536

---

## Answer

### Background

In an 82-year-old female with acute kidney injury (AKI) after ICU admission, pre-existing conditions include congestive heart failure, myocardial infarction, peripheral vascular disease, and the current use of vasopressors, diuretics, and anticoagulants. AKI management must consider potential fluid overload, electrolyte imbalances, and optimize both renal function and cardiovascular stability.

### Evidence Summary

The KDIGO guidelines recommend individualized management based on AKI staging and underlying causes. Volume expansion with isotonic crystalloids and combined usage of vasopressors is advised in cases of vasomotor shock in AKI [KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury (pmid_23499048_p11)].

### Treatment Options

1. **Isotonic Crystalloid Infusion**
   - **Appropriate for:** Initial management of AKI to maintain intravascular volume.
   - **Avoid if:** There is significant risk or history of fluid overload.
   - **Support:** Using isotonic crystalloids, especially when fluid expansion is needed without causing further cardiac stress, aligns with preventing AKI progression [KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury (pmid_23499048_p11)].
   - **Fallback Reasoning:** If isotonic crystalloids are contraindicated due to fluid overload risks, consider vasopressors instead.

2. **Vasopressors with Fluids**
   - **Appropriate for:** Patients with vasomotor shock and AKI risk, maintaining blood pressure and perfusion.
   - **Avoid if:** Hemodynamic instability without volume depletion.
   - **Support:** Vital for maintaining perfusion pressure in shocked states and can be coupled with fluids where appropriate [KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury (pmid_23499048_p11)].
   - **Fallback Reasoning:** If vasopressors are poorly tolerated or ineffective, diuretics as a third-line option may assist in fluid management.

3. **Judicious Use of Diuretics**
   - **Appropriate for:** Fluid management in congestive heart failure and AKI but cautiously.
   - **Avoid if:** Risk of electrolyte imbalance or worsened renal function.
   - **Support:** Diuretics can help manage fluid overload, though they must be used cautiously in AKI, especially when other options are ineffective, and under careful electrolyte monitoring [KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury (pmid_23499048_p11)].

### Conclusion

The optimal management involves using isotonic crystalloids for volume expansion unless contraindicated by fluid overload risks, supplemented by vasopressors to maintain cardiovascular stability if required. Diuretics can be considered if other therapies are insufficient, with careful monitoring to avoid worsening renal or cardiovascular function.

### References

- KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury (pmid_23499048_p11): First-line therapy evidence and safety/interaction data.

---

## Used Sources (with context)

### === DOC pmid_23499048 / KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. / pmid_23499048_p1 ===

**`pmid_23499048_p1_fig_0_c0`** *(image)*

![page_1_fig_0.png](../data/raw/pmid_23499048/page_1_fig_0.png)

**OCR text**

```
KIDNEY DIGO R GLOBAL
```

**`pmid_23499048_p1_fig_1_c0`** *(image)*

![page_1_fig_1.png](../data/raw/pmid_23499048/page_1_fig_1.png)

**`pmid_23499048_p1_fig_2_c0`** *(image)*

![page_1_fig_2.png](../data/raw/pmid_23499048/page_1_fig_2.png)

**`pmid_23499048_p1_fig_3_c0`** *(image)*

![page_1_fig_3.png](../data/raw/pmid_23499048/page_1_fig_3.png)

**`pmid_23499048_p1_fig_4_c0`** *(image)*

![page_1_fig_4.png](../data/raw/pmid_23499048/page_1_fig_4.png)

**`pmid_23499048_p1_fig_5_c0`** *(image)*

![page_1_fig_5.png](../data/raw/pmid_23499048/page_1_fig_5.png)

**`pmid_23499048_p1_fig_6_c0`** *(image)*

![page_1_fig_6.png](../data/raw/pmid_23499048/page_1_fig_6.png)

**`pmid_23499048_p1_fig_7_c0`** *(image)*

![page_1_fig_7.png](../data/raw/pmid_23499048/page_1_fig_7.png)

**`pmid_23499048_p1_fig_8_c0`** *(image)*

![page_1_fig_8.png](../data/raw/pmid_23499048/page_1_fig_8.png)

**`pmid_23499048_p1_t0_c0`** *(text)*

VOLUME 2 | ISSUE 1 | MARCH 2012 http://www.kidney-international.org OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF NEPHROLOGY KDIGO Clinical Practice Guideline for Acute Kidney Injury

### === DOC pmid_23499048 / KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. / pmid_23499048_p11 ===

**`pmid_23499048_p11_t0_c0`** *(text)*

Summary of Recommendation Statements Kidney International Supplements (2012) 2, 8–12; doi:10.1038/kisup.2012.7 http://www.kidney-international.org & 2012 KDIGO Section 2: AKI Definition 2.1.1: AKI is deﬁned as any of the following (Not Graded): K Increase in SCr by X0.3 mg/dl (X26.5 lmol/l) within 48 hours; or K Increase in SCr to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or K Urine volume o0.5 ml/kg/h for 6 hours. 2.1.2: AKI is staged for severity according to the following criteria (Table 2). (Not Graded) 2.1.3: The cause of AKI should be determined whenever possible. (Not Graded) 2.2.1: We recommend that patients be stratiﬁed for risk of AKI according to their susceptibilities and exposures. (1B) 2.2.2: Manage patients according to their susceptibilities and exposures to reduce the risk of AKI (see relevant guideline sections). (Not Graded) 2.2.3: Test patients at increased risk for AKI with measurements of SCr and urine output to detect AKI. (Not Graded) Individualize frequency and duration of monitoring based on patient risk and clinical course. (Not Graded) 2.3.1: Evaluate patients with AKI promptly to determine the cause, with special attention to reversible causes.

**`pmid_23499048_p11_t1_c0`** *(text)*

(Not Graded) K If patients have CKD, manage these patients as detailed in the KDOQI CKD Guideline (Guidelines 7–15). (Not Graded) K If patients do not have CKD, consider them to be at increased risk for CKD and care for them as detailed in the KDOQI CKD Guideline 3 for patients at increased risk for CKD. (Not Graded) Section 3: Prevention and Treatment of AKI 3.1.1: In the absence of hemorrhagic shock, we suggest using isotonic crystalloids rather than colloids (albumin or starches) as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. (2B) 3.1.2: We recommend the use of vasopressors in conjunction with ﬂuids in patients with vasomotor shock with, or at risk for, AKI. (1C) Table 2 | Staging of AKI Stage Serum creatinine Urine output 1 1.5–1.9 times baseline OR X0.3 mg/dl (X26.5 mmol/l) increase o0.5 ml/kg/h for 6–12 hours 2 2.0–2.9 times baseline o0.5 ml/kg/h for X12 hours 3 3.0 times baseline OR Increase in serum creatinine to X4.0 mg/dl (X353.6 mmol/l) OR Initiation of renal replacement therapy OR, In patients o18 years, decrease in eGFR to o35 ml/min per 1.73 m2 o0.

**`pmid_23499048_p11_t2_c0`** *(text)*

3 ml/kg/h for X24 hours OR Anuria for X12 hours 8 Kidney International Supplements (2012) 2, 8–12

**`pmid_23499048_p11_t0_c1`** *(text)*

(Not Graded) 2.2.3: Test patients at increased risk for AKI with measurements of SCr and urine output to detect AKI. (Not Graded) Individualize frequency and duration of monitoring based on patient risk and clinical course. (Not Graded) 2.3.1: Evaluate patients with AKI promptly to determine the cause, with special attention to reversible causes. (Not Graded) 2.3.2: Monitor patients with AKI with measurements of SCr and urine output to stage the severity, according to Recommendation 2.1.2. (Not Graded) 2.3.3: Manage patients with AKI according to the stage (see Figure 4) and cause. (Not Graded) 2.3.4: Evaluate patients 3 months after AKI for resolution, new onset, or worsening of pre-existing CKD.

**`pmid_23499048_p11_t1_c1`** *(text)*

(2B) 3.1.2: We recommend the use of vasopressors in conjunction with ﬂuids in patients with vasomotor shock with, or at risk for, AKI. (1C) Table 2 | Staging of AKI Stage Serum creatinine Urine output 1 1.5–1.9 times baseline OR X0.3 mg/dl (X26.5 mmol/l) increase o0.5 ml/kg/h for 6–12 hours 2 2.0–2.9 times baseline o0.5 ml/kg/h for X12 hours 3 3.0 times baseline OR Increase in serum creatinine to X4.0 mg/dl (X353.6 mmol/l) OR Initiation of renal replacement therapy OR, In patients o18 years, decrease in eGFR to o35 ml/min per 1.73 m2 o0.

**`pmid_23499048_p11_t0_c2`** *(text)*

(Not Graded) 2.3.2: Monitor patients with AKI with measurements of SCr and urine output to stage the severity, according to Recommendation 2.1.2. (Not Graded) 2.3.3: Manage patients with AKI according to the stage (see Figure 4) and cause. (Not Graded) 2.3.4: Evaluate patients 3 months after AKI for resolution, new onset, or worsening of pre-existing CKD.

### === DOC pmid_23499048 / KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. / pmid_23499048_p2 ===

**`pmid_23499048_p2_fig_0_c0`** *(image)*

![page_2_fig_0.png](../data/raw/pmid_23499048/page_2_fig_0.png)

**OCR text**

```
DISEASE KIDNEY GLOBAL
```

**`pmid_23499048_p2_t0_c0`** *(text)*

KDIGO Clinical Practice Guideline for Acute Kidney Injury Tables and Figures iv Notice 1 Work Group Membership 2 KDIGO Board Members 3 Reference Keys 4 Abbreviations and Acronyms 5 Abstract 6 Foreword 7 Summary of Recommendation Statements 8 Section 1: Introduction and Methodology 13 Chapter 1.1: Introduction 13 Chapter 1.2: Methodology 17 Section 2: AKI Definition 19 Chapter 2.1: Definition and classification of AKI 19 Chapter 2.2: Risk assessment 23 Chapter 2.3: Evaluation and general management of patients with and at risk for AKI 25 Chapter 2.4: Clinical applications 28 Chapter 2.5: Diagnostic approach to alterations in kidney function and structure 33 Section 3: Prevention and Treatment of AKI 37 Chapter 3.1: Hemodynamic monitoring and support for prevention and management of AKI 37 Chapter 3.2: General supportive management of patients with AKI, including management of complications 42 Chapter 3.3: Glycemic control and nutritional support 43 Chapter 3.4: The use of diuretics in AKI 47 Chapter 3.5: Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides 50 Chapter 3.6: Growth factor intervention 57 Chapter 3.7: Adenosine receptor antagonists 59 Chapter 3.8: Prevention of aminoglycoside- and amphotericin-related AKI 61 Chapter 3.9: Other methods of prevention of AKI in the critically ill 66 Section 4: Contrast-induced AKI 69 Chapter 4.1: Contrast-induced AKI: definition, epidemiology, and prognosis 69 Chapter 4.2: Assessment of the population at risk for CI-AKI 72 Chapter 4.3: Nonpharmacological prevention strategies of CI-AKI 76 Chapter 4.

**`pmid_23499048_p2_t1_c0`** *(text)*

4: Pharmacological prevention strategies of CI-AKI 80 Chapter 4.5: Effects of hemodialysis or hemofiltration 87 Section 5: Dialysis Interventions for Treatment of AKI 89 Chapter 5.1: Timing of renal replacement therapy in AKI 89 Chapter 5.2: Criteria for stopping renal replacement therapy in AKI 93 Chapter 5.3: Anticoagulation 95 Chapter 5.4: Vascular access for renal replacement therapy in AKI 101 Chapter 5.5: Dialyzer membranes for renal replacement therapy in AKI 105 Chapter 5.6: Modality of renal replacement therapy for patients with AKI 107 Chapter 5.7: Buffer solutions for renal replacement therapy in patients with AKI 111 Chapter 5.8: Dose of renal replacement therapy in AKI 113 Biographic and Disclosure Information 116 Acknowledgments 122 References 124 http://www.kidney-international.

**`pmid_23499048_p2_t2_c0`** *(text)*

org contents & 2012 KDIGO VOL 2 | SUPPLEMENT 1 | MARCH 2012

### === DOC pmid_23499048 / KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. / pmid_23499048_p3 ===

**`pmid_23499048_p3_t0_c0`** *(text)*

TABLES Table 1. Implications of the strength of a recommendation 18 Table 2. Staging of AKI 19 Table 3. Comparison of RIFLE and AKIN criteria for diagnosis and classification of AKI 21 Table 4. Cross-tabulation of patients classified by RIFLE vs. AKIN 21 Table 5. Causes of AKI and diagnostic tests 22 Table 6. Causes of AKI: exposures and susceptibilities for non-specific AKI 23 Table 7. AKI diagnosis 28 Table 8. Overview of the approaches to determine baseline SCr in the application of RIFLE classification in previous studies 29 Table 9. Estimated baseline SCr 29 Table 10. AKI staging 30 Table 11. Definitions of AKI, CKD, and AKD 33 Table 12. Examples of AKI, CKD, and AKD based on GFR and increases in SCr 33 Table 13. Markers of kidney damage in AKD and CKD 35 Table 14. Integrated approach to interpret measures of kidney function and structure for diagnosis of AKI, AKD, and CKD 35 Table 15. CI-AKI risk-scoring model for percutaneous coronary intervention 73 Table 16. Additional radiological measures to reduce CI-AKI 77 Table 17. Potential applications for RRT 91 Table 18. Fluid overload and outcome in critically ill children with AKI 91 Table 19. Overview of the advantages and disadvantages of different anticoagulants in AKI patients 97 Table 20.

**`pmid_23499048_p3_t1_c0`** *(text)*

The RIFLE criteria for AKI 14 Figure 2. Overview of AKI, CKD, and AKD 20 Figure 3. Conceptual model for AKI 20 Figure 4. Stage-based management of AKI 25 Figure 5. Evaluation of AKI according to the stage and cause 26 Figure 6. Chronic Kidney Disease Epidemiology Collaboration cohort changes in eGFR and final eGFR corresponding to KDIGO definition and stages of AKI 34 Figure 7. GFR/SCr algorithm 34 Figure 8. Conceptual model for development and clinical course of AKI 38 Figure 9. Effect of furosemide vs. control on all-cause mortality 48 Figure 10. Effect of furosemide vs. control on need for RRT 48 Figure 11. Effect of low-dose dopamine on mortality 51 Figure 12. Effect of low-dose dopamine on need for RRT 52 Figure 13. Sample questionnaire 73 Figure 14. Risk for contrast-induced nephropathy 78 Figure 15. Bicarbonate vs. saline and risk of CI-AKI 81 Figure 16. NAC and bicarbonate vs. NAC for risk of CI-AKI 85 Figure 17. Flow-chart summary of recommendations 96 Additional information in the form of supplementary materials can be found online at http://www.kdigo.org/clinical_practice_guidelines/AKI.php contents http://www.kidney-international.

**`pmid_23499048_p3_t2_c0`** *(text)*

org & 2012 KDIGO iv Kidney International Supplements (2012) 2, iv

**`pmid_23499048_p3_t0_c1`** *(text)*

Additional radiological measures to reduce CI-AKI 77 Table 17. Potential applications for RRT 91 Table 18. Fluid overload and outcome in critically ill children with AKI 91 Table 19. Overview of the advantages and disadvantages of different anticoagulants in AKI patients 97 Table 20. Catheter and patient sizes 104 Table 21. Typical setting of different RRT modalities for AKI (for 70-kg patient) 107 Table 22. Theoretical advantages and disadvantages of CRRT, IHD, SLED, and PD 108 Table 23. Microbiological quality standards of different regulatory agencies 112 FIGURES Figure 1.

**`pmid_23499048_p3_t1_c1`** *(text)*

NAC for risk of CI-AKI 85 Figure 17. Flow-chart summary of recommendations 96 Additional information in the form of supplementary materials can be found online at http://www.kdigo.org/clinical_practice_guidelines/AKI.php contents http://www.kidney-international.

**`pmid_23499048_p3_t0_c2`** *(text)*

Catheter and patient sizes 104 Table 21. Typical setting of different RRT modalities for AKI (for 70-kg patient) 107 Table 22. Theoretical advantages and disadvantages of CRRT, IHD, SLED, and PD 108 Table 23. Microbiological quality standards of different regulatory agencies 112 FIGURES Figure 1.

